lp-a.org

Aortic stenosis

Genetically predicted lipoprotein(a) shows no causal association with venous thromboembolism or coagulation proteins in a Mendelian randomization study (J Thromb Thrombolysis 2026)

Original title: Genetically predicted lipoprotein(a), first and recurrent venous thromboembolism, and coagulation proteins: evidence against causal relationships

J Thromb Thrombolysis · · 7

Daghlas I, Gill D

This Mendelian randomization study evaluated whether genetically predicted lipoprotein(a) influences venous thromboembolism (VTE) risk and coagulation protein levels. Using variants explaining 36% of lipoprotein(a) variance, researchers tested a 100 nmol/L increase against first VTE (81,190 cases), recurrent VTE (1,775 cases), coronary artery disease (181,522 cases), and calcific aortic stenosis (13,765 cases). Genetically predicted lipoprotein(a) showed a small reduction in first VTE risk (odds ratio [OR] 0.98, 95% confidence interval [CI] 0.96-0.99, P = 0.002), but colocalization analysis (posterior=12%) indicated genetic confounding. There was no association with recurrent VTE (hazard ratio 1.03, 95% CI 0.91-1.16, P = 0.68) or any coagulation proteins. Human genetics does not support a clinically meaningful role for lipoprotein(a) in VTE risk.

Read the paper (DOI)PubMed

Original abstract

Lipoprotein(a) exhibits in vitro antifibrinolytic properties, though it remains uncertain whether this translates into an effect on thromboembolic disease risk. We applied Mendelian randomization (MR) to evaluate the relationship between genetically predicted lipoprotein(a) levels, venous thromboembolism (VTE), and circulating coagulation protein levels. We instrumented lipoprotein(a) using two genetic variants (rs10455872 and rs3798220) that explain 36% of circulating lipoprotein(a) variance. The primary outcomes were first (81,190 cases) and recurrent VTE (1,775 cases). Comparator outcomes included coronary artery disease (181,522 cases) and calcific aortic stenosis (13,765 cases). We performed MR analyses to estimate the association of a genetically predicted 100 nmol/L increase in lipoprotein(a) with each outcome. In exploratory analyses, we tested associations with levels of 35 coagulation proteins in the UK Biobank (n = 46,218) and deCODE (n = 35,559) cohorts. Genetically predicted lipoprotein(a) was associated with a small reduction in risk of first VTE (odds ratio [OR] 0.98, 95% confidence interval [CI] 0.96-0.99, P = 0.002), though this was not supported by colocalization (posterior=12%), suggesting that the MR association was driven by genetic confounding. There was no association with recurrent VTE (hazard ratio 1.03, 95% CI 0.91-1.16, P = 0.68). In contrast, genetically predicted lipoprotein(a) was strongly associated with increased risk of coronary artery disease (OR 1.31, 95% CI 1.29-1.33) and calcific aortic stenosis (OR 1.35, 95% CI 1.30-1.40). After multiple testing correction, genetically predicted lipoprotein(a) had no significant association with any coagulation proteins. Human genetic evidence does not support a clinically meaningful role for lipoprotein(a) in VTE risk. These findings support targeting of lipoprotein(a)-lowering therapies toward atherosclerotic and valvular diseases rather than thromboembolic indications.

aortic stenosisepidemiologygeneticsthrombosis

Summary written by lp-a.org from the published abstract; figures as published. Page updated 14 November 2026. Methods.